Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 26, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 700,000 Ordinary shares of 25 pence each.
- Purchase Date: March 26, 2012.
- Price Range: Highest price paid was 1,423.5 pence per share; lowest price paid was 1,413.5 pence per share.
- Treasury Holdings (Settled): 514,997,927 shares (9.26% of total issued share capital).
- Treasury Holdings (Including Unsettled): 515,817,927 shares (10.23% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,043,895,291 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 700,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior level to 10.23% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. The document notes compliance with the Financial Services Authority's Disclosure and Transparency Rules regarding shareholder notification thresholds.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (514,997,927 settled) against the company's latest capitalization table.
- Confirm the calculation of the 10.23% voting rights held in Treasury including unsettled shares.
- Check the total issued share capital excluding Treasury shares (5,043,895,291) for accurate EPS or ownership percentage calculations.
- Review the price range (1,413.5 to 1,423.5 pence) to assess the cost basis of the repurchase relative to market prices on March 26, 2012.